Experienced in Mixed Connective Tissue Disease

Dr. Elana J. Bernstein

Rheumatology
Trustees Of Columbia University In The City Of New York
622 W 168th St, 
New York, NY 
Offers Telehealth
Experienced in Mixed Connective Tissue Disease
Trustees Of Columbia University In The City Of New York
622 W 168th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elana Bernstein is a Rheumatologist in New York, New York. Dr. Bernstein is rated as an Experienced provider by MediFind in the treatment of Mixed Connective Tissue Disease. Her top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Scleredema, and Scleroma.

Her clinical research consists of co-authoring 98 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Mixed Connective Tissue Disease.

Specialties
Rheumatology
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
622 W 168th St, New York, NY 10032
Other Locations
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
161 Fort Washington Ave, New York, NY 10032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Iloprost
Study Phase: Phase 3
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drug: Belumosudil (KD025)
Study Phase: Phase 2
A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Enrollment Status: Terminated
Publish Date: June 05, 2023
Intervention Type: Drug
Study Drug: Belumosudil
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug, Diagnostic test
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

98 Total Publications

Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.
Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.
Journal: Annals of the American Thoracic Society
Published: April 10, 2025
Similar Doctors
Distinguished in Mixed Connective Tissue Disease
Dr. Peter M. Izmirly
Rheumatology
Distinguished in Mixed Connective Tissue Disease
Dr. Peter M. Izmirly
Rheumatology
560 First Avenue Buyon, Nyu School Of Medicine/clancy Lab Th Room 407, 
New York, NY 
 (6.9 miles away)
212-263-0745
Languages Spoken:
English
See accepted insurances

Peter Izmirly is a Rheumatologist in New York, New York. Dr. Izmirly is rated as a Distinguished provider by MediFind in the treatment of Mixed Connective Tissue Disease. His top areas of expertise are Lupus Nephritis, Systemic Lupus Erythematosus (SLE), Mixed Connective Tissue Disease, and Cutaneous Lupus Erythematosus (CLE).

Distinguished in Mixed Connective Tissue Disease
Dr. Jill P. Buyon
Rheumatology
Distinguished in Mixed Connective Tissue Disease
Dr. Jill P. Buyon
Rheumatology

New York University

324 E 23rd St, 
New York, NY 
 (7.5 miles away)
212-589-6000
Languages Spoken:
English
See accepted insurances

Jill Buyon is a Rheumatologist in New York, New York. Dr. Buyon is rated as a Distinguished provider by MediFind in the treatment of Mixed Connective Tissue Disease. Her top areas of expertise are Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Mixed Connective Tissue Disease, and Sjogren Syndrome.

Distinguished in Mixed Connective Tissue Disease
Dr. Robert G. Lahita
Rheumatology
Distinguished in Mixed Connective Tissue Disease
Dr. Robert G. Lahita
Rheumatology

St Josephs Medical Group PC

703 Main St, 
Paterson, NJ 
 (12.5 miles away)
973-754-6331
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Robert Lahita is a Rheumatologist in Paterson, New Jersey. Dr. Lahita is rated as an Advanced provider by MediFind in the treatment of Mixed Connective Tissue Disease. His top areas of expertise are Mixed Connective Tissue Disease, Fibromyalgia, MASS Phenotype, and Systemic Lupus Erythematosus (SLE). Dr. Lahita is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bernstein's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile